ts23
mAbexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT03001544)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ts23
- ts23
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05948566 | Phase 2 | Mar 31, 2024 | Medical University of South Carolina, National Institute of Neurological Disorders and Stroke (NINDS), Translational Sciences, Inc., University of Arizona, University of Cincinnati |
| NCT05408546 | Phase 2 | Jul 31, 2022 | Translational Sciences, Inc. |
| NCT03001544 | Phase 1 | Jul 1, 2015 | Translational Sciences, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Translational Sciences, Inc. | For profit | 3 | 3 | 2 | 2015 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2024 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1